Earnings Call Summary | Xtant Medical(XTNT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Xtant Medical(XTNT.US) Q1 2024 Earnings Conference
The following is a summary of the Xtant Medical Holdings, Inc. (XTNT) Q1 2024 Earnings Call Transcript:
以下是Xtant Medical Holdings, Inc.（XTNT）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Xtant Medical reported strong Q1 2024 with total revenue of $27.9 million, a 55% increase compared to the same period in 2023.
Gross margin for Q1 2024 improved to 62.1% due to greater scale and efficiencies.
The net loss in Q1 2024 was $4.4 million or $0.03 per share, up from a net loss in Q1 2023.
Long-term debt was increased to $22 million for strategic initiatives.
Full year 2024 revenue outlook was revised to a range of $160 million to $120 million.
Xtant Medical报告称，2024年第一季度表现强劲，总收入为2790万美元，与2023年同期相比增长了55％。
由于规模和效率的提高，2024年第一季度的毛利率提高至62.1％。
2024年第一季度的净亏损为440万美元，合每股亏损0.03美元，高于2023年第一季度的净亏损。
用于战略举措的长期债务增加到2 200万美元。
2024年全年收入前景修正为1.6亿美元至1.2亿美元之间。
Business Progress:
业务进展：
Xtant Medical has expanded its biologics product line, launching a sixth category for wound care.
Xtant's distribution network now has over 650 distributors and has targeted acquisitions to further prospects in biologics.
The company is working towards being less reliant on outside production and is aiming for positive operating cash flow by Q4 2024.
Xtant Medical扩大了其生物制剂产品线，推出了第六类伤口护理。
Xtant的分销网络现在拥有650多家分销商，并以收购为目标，以进一步拓展生物制剂的前景。
该公司正在努力减少对外部生产的依赖，并计划到2024年第四季度实现正的运营现金流。
More details: Xtant Medical IR
更多详情： Xtant 医疗红外线
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。